Thromboembolism - Pipeline Review, H2 2017

Date: July 11, 2017
Pages: 95
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: T1A7D7AF969EN
Leaflet:

Download PDF Leaflet

Thromboembolism - Pipeline Review, H2 2017
Thromboembolism - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thromboembolism - Pipeline Review, H2 2017, provides an overview of the Thromboembolism (Cardiovascular) pipeline landscape.

When a blood clot (thrombus) breaks and travels in the blood, this is called a thromboembolism. Symptoms include warmth, edema, and erythema, and may also include dilated veins (collaterals) on the chest wall or leg. Risk factors include hypertension, diabetes mellitus, cigarette smoking, and high cholesterol levels. Treatment includes anticoagulants, thrombolytic therapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Thromboembolism - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Thromboembolism (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Thromboembolism (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Thromboembolism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 4, 2, 1, 1 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Thromboembolism (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Thromboembolism (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Thromboembolism (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Thromboembolism (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Thromboembolism (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Thromboembolism (Cardiovascular)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Thromboembolism (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Thromboembolism (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Thromboembolism - Overview
Thromboembolism - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Thromboembolism - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Thromboembolism - Companies Involved in Therapeutics Development
Bayer AG
China Biologic Products Inc
Daiichi Sankyo Company Ltd
F. Hoffmann-La Roche Ltd
Gamma Therapeutics Inc
GlycoMimetics Inc
Green Cross Corp
Ionis Pharmaceuticals Inc
Portola Pharmaceuticals Inc
Verseon Corp
Thromboembolism - Drug Profiles
antithrombin III (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
betrixaban - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
edoxaban tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gammarin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GCC-2107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GMI-1271 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IONIS-FXIRx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Lysimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Thromboembolism - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rivaroxaban - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Thrombin for Cardiovascular Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAP-ANV - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRX-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YG-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Thromboembolism - Dormant Projects
Thromboembolism - Discontinued Products
Thromboembolism - Product Development Milestones
Featured News & Press Releases
Jun 28, 2017: U.S. FDA Grants Priority Review of XARELTO (rivaroxaban) sNDA for a 10 mg Dose to Reduce the Risk of Recurrent Venous Thromboembolism
Jun 23, 2017: FDA approved betrixaban (BEVYXXA, Portola) for the prophylaxis of venous thromboembolism (VTE) in adult patients
Apr 28, 2017: Rivaroxaban 10 mg Once Daily from Bayer Submitted to U.S. FDA as Additional Dose Option to Reduce the Risk of Recurrent Venous Thromboembolism
Mar 18, 2017: Bayer's Rivaroxaban Demonstrated Superior Protection Against Recurrent Venous Thromboembolism Compared with Aspirin in EINSTEIN CHOICE Study
Mar 13, 2017: Daiichi Sankyo Announces Large-scale Registry of Venous Thromboembolism in Cancer Patients
Mar 07, 2017: Portola Pharmaceuticals Announces Betrixaban Presentations at ACC.17
Mar 06, 2017: EINSTEIN CHOICE Study with Bayer's Rivaroxaban Accepted for Late-Breaking Clinical Trial Presentation at ACC.17
Feb 08, 2017: FDA Informs Portola Pharmaceuticals at Mid-Cycle Review for Betrixaban That It Has Not Identified Issues that Require an Advisory Committee Meeting
Dec 23, 2016: Portola Pharmaceuticals Announces FDA Accepts New Drug Application for Priority Review and EMA Validates Marketing Authorization Application for Oral, Factor Xa Inhibitor Anticoagulant Betrixaban
Dec 08, 2016: Daiichi Sankyo Announces Initiation of Real-World Study in LIXIANA (edoxaban) Patients Undergoing Diagnostic and Therapeutic Procedures in NVAF and VTE
Dec 06, 2016: New Analysis Shows People with Cancer Who Received XARELTO (rivaroxaban) for Blood Clots Had Fewer ER Visits and Lower Healthcare Costs than Those Given Standard Treatment
Dec 06, 2016: ASH 2016: Explaining the lower bleeding risk of Verseon’s anticoagulants
Nov 28, 2016: Portola Pharmaceuticals Announces Betrixaban Data to be Presented at 2016 American Society of Hematology Annual Meeting and Exposition
Nov 28, 2016: Ten Abstracts on the Use of Bayer's Xarelto in Different Patient Populations Accepted for Presentation at ASH 2016
Nov 28, 2016: Research to Be Presented at ASH Annual Meeting Shows Verseon’s New Class of Anticoagulants Prevents Thrombosis While Preserving Platelet Function
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Thromboembolism, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Thromboembolism - Pipeline by Bayer AG, H2 2017
Thromboembolism - Pipeline by China Biologic Products Inc, H2 2017
Thromboembolism - Pipeline by Daiichi Sankyo Company Ltd, H2 2017
Thromboembolism - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Thromboembolism - Pipeline by Gamma Therapeutics Inc, H2 2017
Thromboembolism - Pipeline by GlycoMimetics Inc, H2 2017
Thromboembolism - Pipeline by Green Cross Corp, H2 2017
Thromboembolism - Pipeline by Ionis Pharmaceuticals Inc, H2 2017
Thromboembolism - Pipeline by Portola Pharmaceuticals Inc, H2 2017
Thromboembolism - Pipeline by Verseon Corp, H2 2017
Thromboembolism - Dormant Projects, H2 2017
Thromboembolism - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Thromboembolism, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Targets, H2 2017
Number of Products by Stage and Targets, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
Skip to top


Venous Thromboembolism - Pipeline Review, H2 2015 US$ 2,000.00 Nov, 2015 · 83 pages
Constipation - Pipeline Review, H2 2017 US$ 2,000.00 Jul, 2017 · 119 pages

Ask Your Question

Thromboembolism - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: